Information Library

Results for: White Papers - Business transformation

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Reinventing Biopharma

    February 1, 2012
    The biopharmaceutical industry today is facing a multifaceted “value challenge.”

  • FSPs: Ranging from Tactical to Strategic Models

    January 4, 2012
    Biopharma companies can choose from a range of outsourcing models as they seek to respond effectively to the ever-changing conditions in the New Health.

  • Partnering to Maximize Rewards in Pharmerging Markets

    September 15, 2011
    In the past few years so-called “pharmerging” markets have been heralded as the hottest growth area for biopharmaceutical drugs. With large populations, growing disposable income and unmet medical needs, these markets have seen doubledigit growth rates in pharmaceutical spending.

  • The New Health Alliance

    January 10, 2011
    Biopharmaceutical companies must explore alternative strategic alliances that meet the needs of the New Health and produce medicines that demonstrate value to the entire constellation of stakeholders.

  • 2010 Executive Vision Forum Insight Report

    November 18, 2010
    The 2010 forum presented a venue for executives and key opinion leaders to discuss and debate the converging forces now reshaping the industry.

  • Using Real-Time Data to Drive Better Decisions, Faster

    September 30, 2010
    This white paper examines the advantages afforded by access to real-time data during the course of a clinical trial.

  • Shaping Clinical Transformation

    November 18, 2009
    A summary of key insights exchanged between pharma executives at the inaugural Quintiles Consulting Executive Vision Forum.

  • Rebalancing Risk to Transform R&D

    June 3, 2009
    A strategic approach to re-balancing the main components of biopharma company risk: portfolio, operational and resource.

  • White Paper: EDC Past, Present and Future

    March 25, 2009
    Quintiles has run EDC at more than 19,000 trial sites worldwide, covering more than 310,000 subjects.

  • Monitoring for Quality

    May 22, 2008
    Scott Cooley, Executive Director, Phase IIIb/IV Product Management, Quintiles, discusses innovative and traditional resources in a risk-based monitoring program.

Page 1 of 1 (10 results)

Subscribe to Email Based on Your Interests

Set preferences